230 related articles for article (PubMed ID: 12605562)
1. Novel antibacterial agents for the treatment of serious Gram-positive infections.
Abbanat D; Macielag M; Bush K
Expert Opin Investig Drugs; 2003 Mar; 12(3):379-99. PubMed ID: 12605562
[TBL] [Abstract][Full Text] [Related]
2. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
3. Newer treatment options for skin and soft tissue infections.
Raghavan M; Linden PK
Drugs; 2004; 64(15):1621-42. PubMed ID: 15257625
[TBL] [Abstract][Full Text] [Related]
4. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
Rubinstein E; Bompart F
J Antimicrob Chemother; 1997 May; 39 Suppl A():139-43. PubMed ID: 9511078
[TBL] [Abstract][Full Text] [Related]
5. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
Napolitano LM
Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
[TBL] [Abstract][Full Text] [Related]
6. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
7. Novel agents for resistant Gram-positive infections--a review.
Strahilevitz J; Rubinstein E
Int J Infect Dis; 2002 Mar; 6 Suppl 1():S38-46. PubMed ID: 12044288
[TBL] [Abstract][Full Text] [Related]
8. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
Lamb HM; Figgitt DP; Faulds D
Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
[TBL] [Abstract][Full Text] [Related]
9. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.
Jones RN; Low DE; Pfaller MA
Diagn Microbiol Infect Dis; 1999 Feb; 33(2):101-12. PubMed ID: 10091033
[TBL] [Abstract][Full Text] [Related]
10. Antibiotics for treatment of resistant gram-positive coccal infections.
Al-Tatari H; Abdel-Haq N; Chearskul P; Asmar B
Indian J Pediatr; 2006 Apr; 73(4):323-34. PubMed ID: 16816494
[TBL] [Abstract][Full Text] [Related]
11. Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.
Guay DR
Pharmacotherapy; 2004 Jan; 24(1):58-68. PubMed ID: 14740788
[TBL] [Abstract][Full Text] [Related]
12. Oxazolidinone antibiotics.
Diekema DJ; Jones RN
Lancet; 2001 Dec; 358(9297):1975-82. PubMed ID: 11747939
[TBL] [Abstract][Full Text] [Related]
13. Future trends in the treatment of serious Gram-positive infections.
Metzger R; Bonatti H; Sawyer R
Drugs Today (Barc); 2009 Jan; 45(1):33-45. PubMed ID: 19271030
[TBL] [Abstract][Full Text] [Related]
14. Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria.
Appelbaum PC; Jacobs MR
Curr Opin Microbiol; 2005 Oct; 8(5):510-7. PubMed ID: 16098786
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens].
Manfredi R
Recenti Prog Med; 2007 Mar; 98(3):143-54. PubMed ID: 17484159
[TBL] [Abstract][Full Text] [Related]
16. Linezolid: a review of its use in the management of serious gram-positive infections.
Perry CM; Jarvis B
Drugs; 2001; 61(4):525-51. PubMed ID: 11324682
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.
Lee SY; Kuti JL; Nicolau DP
Surg Infect (Larchmt); 2005; 6(3):283-95. PubMed ID: 16201938
[TBL] [Abstract][Full Text] [Related]
19. New antibiotic agents: problems and prospects.
Weber DJ; Rutala WA
Surg Infect (Larchmt); 2005; 6 Suppl 2():S-97-107. PubMed ID: 23577500
[TBL] [Abstract][Full Text] [Related]
20. Gram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases Pharmacists.
Akins RL; Haase KK
Pharmacotherapy; 2005 Jul; 25(7):1001-10. PubMed ID: 16006278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
